Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ.

Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24.

2.

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors.

Bendell JC, Hong DS, Burris HA 3rd, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R.

Cancer Chemother Pharmacol. 2014 Jul;74(1):125-30. doi: 10.1007/s00280-014-2480-2. Epub 2014 May 13.

PMID:
24819685
3.

Refining endpoints in brain tumor clinical trials.

Meyers CA, Rock EP, Fine HA.

J Neurooncol. 2012 Jun;108(2):227-30. doi: 10.1007/s11060-012-0813-8. Epub 2012 Mar 27.

PMID:
22451194
4.

GCP data quality for early clinical development.

Rock EP, Molloy VJ, Humphrey JS.

Clin Cancer Res. 2010 Mar 15;16(6):1756-63. doi: 10.1158/1078-0432.CCR-09-3267. Epub 2010 Mar 9.

5.

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N.

Am Heart J. 2009 May;157(5):827-36, 836.e1. doi: 10.1016/j.ahj.2009.02.020. Review.

PMID:
19376308
6.

Patient-reported outcomes to support medical product labeling claims: FDA perspective.

Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, O'Neill R, Kennedy DL.

Value Health. 2007 Nov-Dec;10 Suppl 2:S125-37. Review.

7.

Patient-reported outcomes assessment in cancer trials: taking stock, moving forward.

Lipscomb J, Reeve BB, Clauser SB, Abrams JS, Bruner DW, Burke LB, Denicoff AM, Ganz PA, Gondek K, Minasian LM, O'Mara AM, Revicki DA, Rock EP, Rowland JH, Sgambati M, Trimble EL.

J Clin Oncol. 2007 Nov 10;25(32):5133-40. Review.

PMID:
17991933
8.

Patient-reported outcomes supporting anticancer product approvals.

Rock EP, Kennedy DL, Furness MH, Pierce WF, Pazdur R, Burke LB.

J Clin Oncol. 2007 Nov 10;25(32):5094-9. Review.

PMID:
17991927
9.

Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products.

Rock EP, Scott JA, Kennedy DL, Sridhara R, Pazdur R, Burke LB.

J Natl Cancer Inst Monogr. 2007;(37):27-30.

PMID:
17951228
10.

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R.

Clin Cancer Res. 2007 Mar 1;13(5):1367-73. Review.

11.

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R.

Oncologist. 2007 Jan;12(1):107-13.

12.
14.

CDR3 length in antigen-specific immune receptors.

Rock EP, Sibbald PR, Davis MM, Chien YH.

J Exp Med. 1994 Jan 1;179(1):323-8.

15.
16.

T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen.

Ehrich EW, Devaux B, Rock EP, Jorgensen JL, Davis MM, Chien YH.

J Exp Med. 1993 Aug 1;178(2):713-22.

17.

Transfer of putative complementarity-determining region loops of T cell receptor V domains confers toxin reactivity but not peptide/MHC specificity.

Patten PA, Rock EP, Sonoda T, Fazekas de St Groth B, Jorgensen JL, Davis MM.

J Immunol. 1993 Mar 15;150(6):2281-94.

PMID:
7680688
18.

Characterization and localization of Plasmodium falciparum surface antigens on infected erythrocytes from west African patients.

van Schravendijk MR, Rock EP, Marsh K, Ito Y, Aikawa M, Neequaye J, Ofori-Adjei D, Rodriguez R, Patarroyo ME, Howard RJ.

Blood. 1991 Jul 1;78(1):226-36.

PMID:
2070055
19.

A possible basis for major histocompatibility complex-restricted T-cell recognition.

Davis MM, Chien YH, Bjorkman PJ, Elliott JF, Iwashima M, Rock EP, Patten PA.

Philos Trans R Soc Lond B Biol Sci. 1989 Jun 12;323(1217):521-4.

PMID:
2569209
20.

Passage of Salmonella through polarized epithelial cells: role of the host and bacterium.

Finlay BB, Fry J, Rock EP, Falkow S.

J Cell Sci Suppl. 1989;11:99-107. Review.

PMID:
2693464
21.
22.

A portion of the Pf155/RESA antigen of Plasmodium falciparum is accessible on the surface of infected erythrocytes.

Saul A, Maloy WL, Rock EP, Howard RJ.

Immunol Cell Biol. 1988 Aug;66 ( Pt 4):269-76.

PMID:
3154921
23.

The adult T-cell receptor delta-chain is diverse and distinct from that of fetal thymocytes.

Elliott JF, Rock EP, Patten PA, Davis MM, Chien YH.

Nature. 1988 Feb 18;331(6157):627-31.

PMID:
2963227
24.

Two approximately 300 kilodalton Plasmodium falciparum proteins at the surface membrane of infected erythrocytes.

Howard RJ, Barnwell JW, Rock EP, Neequaye J, Ofori-Adjei D, Maloy WL, Lyon JA, Saul A.

Mol Biochem Parasitol. 1988 Jan 15;27(2-3):207-23.

PMID:
3278227
25.

Thrombospondin mediates the cytoadherence of Plasmodium falciparum-infected red cells to vascular endothelium in shear flow conditions.

Rock EP, Roth EF Jr, Rojas-Corona RR, Sherwood JA, Nagel RL, Howard RJ, Kaul DK.

Blood. 1988 Jan;71(1):71-5.

PMID:
3275476
26.

Comparative analysis of the Plasmodium falciparum histidine-rich proteins HRP-I, HRP-II and HRP-III in malaria parasites of diverse origin.

Rock EP, Marsh K, Saul AJ, Wellems TE, Taylor DW, Maloy WL, Howard RJ.

Parasitology. 1987 Oct;95 ( Pt 2):209-27.

PMID:
3320887
27.

Ultrastructure of the erythrocytic stages of Plasmodium malariae.

Atkinson CT, Aikawa M, Rock EP, Marsh K, Andrysiak PM, Campbell GH, Collins WE, Howard RJ.

J Protozool. 1987 Aug;34(3):267-74.

PMID:
3309268

Supplemental Content

Support Center